Melatonin is one of the most established ingredients in sleep products, but its role is often simplified to “helping people fall asleep.”
For product developers, there is more to consider. Melatonin is closely linked to the body's circadian rhythm, and factors such as dose, timing, release profile, and formulation can all influence how it performs in a finished product.
So how does melatonin work, and what should formulators consider when developing modern sleep supplements?
Melatonin is a hormone naturally produced by the pineal gland, with production typically increasing in the evening as part of the body's circadian rhythm.
Rather than acting simply as a sedative, melatonin functions as a biological timing signal. Its relationship with the sleep-wake cycle is one reason it has become an important ingredient in products designed to support sleep onset and circadian rhythm regulation.
Exogenous melatonin can therefore be particularly relevant when the goal of a formulation is to support the body's natural sleep timing rather than simply promote general relaxation.
Research on exogenous melatonin has consistently shown that its effects can depend on how and when it is administered.
A systematic review of randomized controlled trials found that melatonin can reduce sleep onset latency and increase total sleep time, while also identifying administration timing and dose as important factors influencing outcomes.
Pharmacokinetic research also highlights an important formulation consideration. Oral immediate-release melatonin is absorbed relatively quickly but has a short elimination half-life and relatively low, variable bioavailability. A systematic review of clinical pharmacokinetic studies reported oral bioavailability ranging from approximately 9% to 33%, with substantial variation between individuals and study conditions.
This has encouraged the development of different delivery formats, including immediate-release, prolonged-release, and delayed-release formulations.
A systematic review examining melatonin formulations found that different formulations and doses produced different pharmacokinetic profiles, which may influence their effects on sleep. However, the available evidence was not sufficient to identify one formulation as universally optimal for every sleep or circadian application.
More recent clinical studies continue to support this formulation perspective. For example, extended-release melatonin has been shown to produce a slower rise in plasma concentration and a longer-lasting exposure compared with immediate-release melatonin.
For formulators, the key takeaway is simple: melatonin is not only about how much is used, but also about how the ingredient is delivered.
The short half-life and rapid pharmacokinetics of conventional oral melatonin create an interesting formulation challenge.
An immediate-release format may be suitable when the primary product positioning is around sleep onset, while a prolonged- or controlled-release approach may be considered when longer exposure is desired.
Research comparing immediate- and prolonged-release formulations has demonstrated clear differences in plasma concentration profiles. In one randomized crossover study, prolonged-release melatonin produced a later peak concentration and longer exposure than an immediate-release formulation.
This does not mean that prolonged release is automatically better. The appropriate format depends on the intended product positioning, target population, formulation matrix, dosage form, and regulatory requirements.
For brands, several factors may therefore need to be considered:
Target sleep outcome: sleep onset, sleep maintenance, or broader sleep support
Release profile: immediate, prolonged, or delayed release
Dose and timing: how much melatonin is delivered and when
Ingredient compatibility: interaction with other functional ingredients in the formula
Product format: capsule, tablet, powder, gummy, liquid, or other delivery system
Regulatory requirements: permitted use, dosage, and claims vary across markets
This makes melatonin an interesting example of why delivery technology and formulation strategy can be just as important as ingredient selection.
Melatonin is particularly relevant to formulations designed around:
Circadian rhythm support
Sleep onset
Sleep-wake cycle regulation
Time-of-administration strategies
Combination sleep formulations
At the same time, melatonin does not directly address every factor that can interfere with sleep.
Stress, mental arousal, relaxation, and neurotransmitter balance can all play different roles in the overall sleep experience. This is where complementary ingredients can become relevant.
For example, GABA, L-theanine, and magnesium glycinate can be incorporated into formulations focused on relaxation and neurotransmitter balance, while Ashwagandha can be used in formulations targeting stress adaptation.
This broader formulation strategy is the basis of NF TriSolve® Sleep Health Solution.
Within the solution, melatonin serves as the core ingredient for Pathway 1 — Circadian Rhythm Support, addressing the timing component of sleep.
The formulation combines three complementary pathways:
Pathway 1 — Circadian Rhythm Support Melatonin
Pathway 2 — Neurotransmitter Balance GABA, L-theanine, and magnesium glycinate
Pathway 3 — Stress Adaptation Ashwagandha
Rather than relying on melatonin alone, this approach considers sleep as a multi-dimensional process involving circadian rhythm, neural relaxation, and stress adaptation.
NF TriSolve® is further supported by Natural Field's co-loaded liposomal delivery technology, which co-encapsulates Ashwagandha and melatonin within a liposomal system.
For product developers, this creates a different way to think about melatonin: not simply as a standalone sleep ingredient, but as one component within a broader formulation and delivery strategy.
Melatonin remains an important ingredient in sleep product development because of its close relationship with the body's circadian rhythm.
Current research also highlights an important formulation lesson: dose, timing, and delivery profile can influence how melatonin behaves in the body.
For modern sleep products, the opportunity is therefore not simply to add melatonin, but to consider how melatonin fits within the overall formulation and how complementary ingredients can address other dimensions of sleep health.
That is the approach behind NF TriSolve® Sleep Health Solution—combining melatonin with complementary functional ingredients and advanced co-loaded liposomal delivery technology to support the development of next-generation sleep products.
1. Li Y, et al. Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review of Randomized Controlled Trials and Dose-Response Meta-Analysis. Journal of Pineal Research. 2024.
2. Harpsøe NG, et al. Clinical Pharmacokinetics of Melatonin: A Systematic Review. European Journal of Clinical Pharmacology. 2015.
3. Anderson KN, et al. Pharmacokinetics of Exogenous Melatonin in Relation to Formulation, and Effects on Sleep: A Systematic Review. Sleep Medicine Reviews. 2021.
4. Zisapel N, et al. A Randomized, Double-Blind, Crossover Study to Investigate the Pharmacokinetics of Extended-Release Melatonin Compared to Immediate-Release Melatonin in Healthy Adults. 2023.
5. Del Casale A, et al. The Use of Prolonged-Release Melatonin in Circadian Medicine: A Systematic Review. Minerva Medica. 2024.
Professor and Ph.D. Supervisor, School of Pharmaceutical Sciences, Southern Medical University. Head of the Functional Ingredient R&D Center, Natural Field. Professor Chong Li is a distinguished researcher in the field of advanced drug delivery systems and pharmaceutical technology innovation.
EN
es 
jp 
ko 
fr 
de 
it 
ru 
pt 
th 
ar 
ms 
